<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Biogen Inc. BIIB, -6.70% were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how the new rule proposing limited access to Biogen’s Alzheimer’s disease drug Aduhelm (and other drugs in the same class of treatments) to clinical trials in order to receive federal reimbursement plays out.
...read full article on Market Watch
